Linsitinib (OSI-906)

Name: Linsitinib (OSI-906)
Brand: Selleck Chemicals
SKU: S1091
Rating: 5 (91 reviews)

For research use only.

Catalog No.S1091

91 publications

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Selleck's Linsitinib (OSI-906) has been cited by 91 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 24;539(7630):570-574.

PubMed: 27820945 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

FASEB J, 2020, 34(4):5363-5388

PubMed: 32067272 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):920-926

PubMed: 31871269 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2020, 16;11:219

PubMed: 32373071 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(1):186-194

PubMed: 31993315 ( click the link to review the publication )

Nat Commun, 2019, 10(1):518

PubMed: 30705270 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32668

PubMed: 31490549 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )
FASEB J, 2019, 33(10):11210-11222

PubMed: 31291762 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

J Gerontol A Biol Sci Med Sci, 2019, 74(9):1375-1385

PubMed: 30329021 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:5497467

PubMed: 31467485 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1777

PubMed: 29725014 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2546

PubMed: 29959327 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

Oncotarget, 2018, 9(10):8810-8822

PubMed: 29507656 ( click the link to review the publication )
Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(11):895-903

PubMed: 28696156 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )

J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )

Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103465-103476

PubMed: 29262576 ( click the link to review the publication )

Hepatology, 2017, 66(6):2002-2015

PubMed: 28653763 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(6):481-93

PubMed: 27185872 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )
J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(17):2991-3004

PubMed: 26100015 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Diabetes, 2013, 62(10):3448-58

PubMed: 23801577 ( click the link to review the publication )

BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )

Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A4-Fuk	MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMEK4NFYh\|ryP	MVLTRW5ITVJ?
KS-1	NU\nVIJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7hTWM2OD1yLkCzPFM2KM7:TR?=	NVrJWnNGW0GQR1XS
TE-11	NXT2OIkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHoTWM2OD1yLkC3PFIzKM7:TR?=	NEfUWWdUSU6JRWK=
EW-1	M3nDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLZTWM2OD1yLkC4OVg2KM7:TR?=	M3vEZnNCVkeHUh?=
HMV-II	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHJPXJKSzVyPUCuNFg5PDZizszN	MXTTRW5ITVJ?
COLO-205	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPMTWM2OD1yLkGwOFU1KM7:TR?=	MVvTRW5ITVJ?
ES1	NEDucldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFyye5VKSzVyPUCuNVA3QTZizszN	NFrWV4RUSU6JRWK=
GDM-1	Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3e5TGlEPTB;MD6xN\|Y4OiEQvF2=	MYHTRW5ITVJ?
ML-2	NEHUOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1niU2lEPTB;MD6xOVg6PiEQvF2=	Mn;LV2FPT0WU
Saos-2	NGnOd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjN[Ip5UUN3ME2wMlE3PTJ4IN88US=>	MVPTRW5ITVJ?
NCI-H1355	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwMUixN\|Uh\|ryP	NETXVHNUSU6JRWK=
G-401	M1HZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvXXYFHUUN3ME2wMlE5OjNizszN	M{DiO3NCVkeHUh?=
EW-16	NF2wVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{D4TmlEPTB;MD6xPFc4PyEQvF2=	MV3TRW5ITVJ?
EW-7	NEDP[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Pq[mlEPTB;MD6xPFg5OSEQvF2=	M4nMdHNCVkeHUh?=
NCI-H727	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwMUm3PVQh\|ryP	NYWwUJVVW0GQR1XS
LCLC-97TM1	NE\sbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\3e5FKSzVyPUCuNlA6PTVizszN	MlHIV2FPT0WU
NCI-H650	NUXaPW1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjzfFVKSzVyPUCuNlE{QDRizszN	NGPYWndUSU6JRWK=
NCI-H2122	NHjCOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LpZ2lEPTB;MD6yN\|I6QSEQvF2=	M{CwcXNCVkeHUh?=
SK-N-DZ	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWSzb4F6UUN3ME2wMlI{Pjl6IN88US=>	NGnPc3ZUSU6JRWK=
HT-29	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWq4XYxnUUN3ME2wMlI1OjR6IN88US=>	MX;TRW5ITVJ?
LB771-HNC	NF3JXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHEWmNkUUN3ME2wMlI2QTF3IN88US=>	MVnTRW5ITVJ?
HT-144	M3v3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwMk[xPVEh\|ryP	NXLnSoU3W0GQR1XS
LAN-6	NYiwcnV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULHRnlOUUN3ME2wMlI3OzR6IN88US=>	MoTjV2FPT0WU
EW-18	Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzD[olDUUN3ME2wMlI4ODBzIN88US=>	NH\GV4pUSU6JRWK=
LS-1034	NGG5Wo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwMkexN\|Ih\|ryP	M37aNHNCVkeHUh?=
EW-11	M2DQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlroTWM2OD1yLkK4OFMzKM7:TR?=	NH3NOXhUSU6JRWK=
SNU-C1	NUL3[\|ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LuT2lEPTB;MD6yPVMyOyEQvF2=	M2rNO3NCVkeHUh?=
RS4-11	NIX0XJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwM{O3OVgh\|ryP	M4DCRnNCVkeHUh?=
ES4	M2\KOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwNEGwN\|gh\|ryP	NWnScGFKW0GQR1XS
COLO-320-HSR	NEftPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwNEGzOlgh\|ryP	NYnIToplW0GQR1XS
NB10	NGXwTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XodmlEPTB;MD60OVQ{PyEQvF2=	MV7TRW5ITVJ?
BFTC-905	NUWyT4p5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwNE[3OVgh\|ryP	MkfGV2FPT0WU
A375	NWm5OlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHaenZKSzVyPUCuOFc3OTdizszN	MVfTRW5ITVJ?
SJRH30	NG[1PIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HGUGlEPTB;MD61NFgzOiEQvF2=	NXrpbIU2W0GQR1XS
NOS-1	NYDSdppHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLFTFZKSzVyPUCuOVIzPjdizszN	M{TxdHNCVkeHUh?=
SIG-M5	NXW1NJVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M130fmlEPTB;MD61N\|U2PyEQvF2=	NUDZZmtLW0GQR1XS
DOK	MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;y[HpPUUN3ME2wMlU2PiEQvF2=	NHLQ[HRUSU6JRWK=
NB69	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwNUiyOVch\|ryP	MkTpV2FPT0WU
SK-NEP-1	NF[zO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Tx[GlEPTB;MD62NFI{PiEQvF2=	M2PQOHNCVkeHUh?=
SK-MM-2	NFTlNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPYTWM2OD1yLk[1OFkyKM7:TR?=	MVLTRW5ITVJ?
NCI-H358	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm[0TWM2OD1yLk[3NFgzKM7:TR?=	NVTDTnVPW0GQR1XS
RH-1	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvIdVN2UUN3ME2wMlc1QDV7IN88US=>	MU\TRW5ITVJ?
NH-12	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4q4W2lEPTB;MD63OlA1PiEQvF2=	NUfYNINsW0GQR1XS
TE-12	MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1L5c2lEPTB;MD63OlQ5PiEQvF2=	MkTJV2FPT0WU
COLO-668	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkn1TWM2OD1yLki0OlY3KM7:TR?=	NFzLNIFUSU6JRWK=
PANC-08-13	NGL3PJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUm4S4RQUUN3ME2wMlg3Ozd5IN88US=>	NXHvPJlWW0GQR1XS
HCC2998	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwOEiyOlMh\|ryP	MnHMV2FPT0WU
ABC-1	NUP0PXVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXX6SFUxUUN3ME2wMlkxOzV{IN88US=>	MUXTRW5ITVJ?
ES6	NH3iW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzxPXVKSzVyPUCuPVExPjZizszN	MoTWV2FPT0WU
SNU-387	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwOUmzPVMh\|ryP	NHPIbopUSU6JRWK=
CMK	NHjST2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LqTGlEPTB;MD65PVkzQSEQvF2=	NVyxcpF2W0GQR1XS
SJSA-1	NFqzXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjaUZdTUUN3ME2xMlA{PjV\|IN88US=>	NF7PfoNUSU6JRWK=
SIMA	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfDO3RKSzVyPUGuNFY5OjVizszN	M{HmdnNCVkeHUh?=
ES3	NGHDdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HkUGlEPTB;MT6xNlI6PyEQvF2=	NGTlNpVUSU6JRWK=
IGROV-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnH1TWM2OD1zLkG1OFQ1KM7:TR?=	MlTsV2FPT0WU
MEL-JUSO	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jJVGlEPTB;MT6xOVc2QSEQvF2=	NIXKcXZUSU6JRWK=
T84	M2\6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTZe2VKSzVyPUGuNlA6OTRizszN	MXfTRW5ITVJ?
CAL-85-1	M{\OV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTvTWM2OD1zLkKzNVM5KM7:TR?=	NXfMTIRsW0GQR1XS
RD	NG\SU\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVqyXVZTUUN3ME2xMlI3PDV3IN88US=>	MojuV2FPT0WU
TE-8	NVy2dodET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3SxS2lEPTB;MT6zNVQ3OiEQvF2=	MWfTRW5ITVJ?
L-363	NVfLN5hlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHNTWM2OD1zLkO0NlA5KM7:TR?=	NEXqTmlUSU6JRWK=
EKVX	MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIK4PGxKSzVyPUGuN\|Q2PjhizszN	M3:4T3NCVkeHUh?=
SK-MEL-3	M1rSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkflTWM2OD1zLkS4OVU3KM7:TR?=	NXrMWo14W0GQR1XS
TGBC24TKB	MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDsTWM2OD1zLkWwNVk{KM7:TR?=	MlixV2FPT0WU
NCI-H1770	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDYPZVKSzVyPUGuOVEyOTNizszN	MnnyV2FPT0WU
HuH-7	NX\lZodIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrUc\|lKSzVyPUGuOlAxQThizszN	NHSxNohUSU6JRWK=
HL-60	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHlXmpKSzVyPUGuOlY6OjhizszN	M{\nOXNCVkeHUh?=
TE-1	MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHvTWM2OD1zLkewPVQ2KM7:TR?=	NGLuemhUSU6JRWK=
LC-2-ad	M3flUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTFwN{O4PFch\|ryP	MkG5V2FPT0WU
LB647-SCLC	M1KxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXBWWtKSzVyPUGuO\|Y2QDNizszN	NEPZSopUSU6JRWK=
NCI-H2171	NFHJOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXDUoRFUUN3ME2xMlc4PzF4IN88US=>	NX\0cYxoW0GQR1XS
SK-PN-DW	MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fIW2lEPTB;MT65NVI6QCEQvF2=	NHLMZm1USU6JRWK=
MC-IXC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHwTWM2OD1zLkm4PVgh\|ryP	NIrFdmlUSU6JRWK=
LS-513	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTJwMEWzNFUh\|ryP	NEHHPHdUSU6JRWK=
EW-3	M2Xnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnSVHFKSzVyPUKuNFk5PDRizszN	MUjTRW5ITVJ?
OPM-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkmwTWM2OD1{LkGwNkDPxE1?	MlrwV2FPT0WU
LP-1	M2DsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjvd4ZKSzVyPUKuNlU5ODdizszN	MkHKV2FPT0WU
LU-134-A	M2DQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fHbmlEPTB;Mj6yO\|ch\|ryP	MVvTRW5ITVJ?
CP66-MEL	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLYOYdKSzVyPUKuNlkxOTRizszN	M2LpeHNCVkeHUh?=
HCC1143	NHjIU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHOTWM2OD1{LkS1N\|Y5KM7:TR?=	NGDoWWhUSU6JRWK=
LOXIMVI	M2jJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLzXJE3UUN3ME2yMlYxOjFizszN	MUPTRW5ITVJ?
TE-10	NXT6U2I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTkR2lKSzVyPUKuO\|A5OzhizszN	MVPTRW5ITVJ?
NCI-H1882	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX:0S2FsUUN3ME2yMlc2OjJ5IN88US=>	M3vMTHNCVkeHUh?=
CHP-126	NEjhdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\wRlVLUUN3ME2yMlc3OzF5IN88US=>	MkTIV2FPT0WU
NCI-H1623	NVHDZoRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zR[WlEPTB;Mj65NlAzPCEQvF2=	M3jES3NCVkeHUh?=
GB-1	NX35PIhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrUVnNxUUN3ME2yMlk{PDB2IN88US=>	M1rScHNCVkeHUh?=
RCC10RGB	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;0XoJKSzVyPUKuPVUzQDFizszN	M2PRUXNCVkeHUh?=
NCI-H2141	M{HtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXRTWM2OD1{Lkm2PFk3KM7:TR?=	MXnTRW5ITVJ?
GI-ME-N	MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDIR3RKSzVyPUOuNFA2PjVizszN	NIjUSnhUSU6JRWK=
NCI-H526	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTNwMESwPFUh\|ryP	M2[2XHNCVkeHUh?=
NCI-H747	MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\LelNFUUN3ME2zMlA1QTl{IN88US=>	NIHye2VUSU6JRWK=
SNU-423	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTNwMkCzNVMh\|ryP	NEHacZVUSU6JRWK=
A427	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\OWWdKSzVyPUOuNlU3QTlizszN	NXiycHVQW0GQR1XS
CAL-12T	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHOzSG1KSzVyPUOuOFA4OTNizszN	NGr6VZlUSU6JRWK=
LU-99A	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV:yd25xUUN3ME2zMlQ4OTB3IN88US=>	MVrTRW5ITVJ?
MS-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\5PIxKSzVyPUOuOVM1OjlizszN	MYDTRW5ITVJ?
SK-LU-1	NFjWZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DUT2lEPTB;Mz63OlI6PSEQvF2=	NET4PFhUSU6JRWK=
SW837	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTmVFFKSzVyPUOuO\|Y{OzNizszN	NXnsNWxRW0GQR1XS
ES8	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYH6SZc3UUN3ME2zMlg{QDd5IN88US=>	MnzXV2FPT0WU
MZ2-MEL	M1jNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvwUHhKSzVyPUOuPVIxQDZizszN	MlXEV2FPT0WU
TGW	MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLHUXpvUUN3ME20MlAyOzFzIN88US=>	M1[wcXNCVkeHUh?=
GP5d	NFP3ZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3P6fmlEPTB;ND6wOVM3OiEQvF2=	NV7HSph6W0GQR1XS
BB49-HNC	Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGqzOZdKSzVyPUSuNVUzOTNizszN	MXfTRW5ITVJ?
NB13	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\OTWM2OD12LkK2PFg4KM7:TR?=	MkTjV2FPT0WU
NTERA-S-cl-D1	NUjjdnFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHxOlhKSzVyPUSuNlg3OTVizszN	M4PBZXNCVkeHUh?=
NCI-H1648	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrGUWxKSzVyPUSuNlk5OTlizszN	MXTTRW5ITVJ?
LCLC-103H	NYDsVFdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTRwM{KxPVUh\|ryP	MmnyV2FPT0WU
LS-411N	NFTlXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTRwNES4PFUh\|ryP	NHX3No1USU6JRWK=
NCI-H1092	NV3wN4RNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzhTWM2OD12LkS1Olg4KM7:TR?=	MYPTRW5ITVJ?
PANC-10-05	M1nL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\Ve4ZKSzVyPUSuOlk5PCEQvF2=	MYjTRW5ITVJ?
DK-MG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\0TWM2OD12LkiwPVM{KM7:TR?=	NWfWeIltW0GQR1XS
OVCAR-5	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTRwOEGyNlYh\|ryP	MojiV2FPT0WU
CAL-39	M4O3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13mZ2lEPTB;ND64O\|Y4KM7:TR?=	MVHTRW5ITVJ?
TE-441-T	M1[2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7SZXNKSzVyPUSuPVA2OzdizszN	NULoOpk1W0GQR1XS
MOLT-16	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HhSGlEPTB;ND65OVI2OyEQvF2=	NVnqWYlKW0GQR1XS
MCF7	NELEUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjGTWM2OD13LkG0OVE4KM7:TR?=	Mnv6V2FPT0WU
CAPAN-1	M4TyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrvSGRvUUN3ME21MlI2PzB5IN88US=>	MV;TRW5ITVJ?
PSN1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jWU2lEPTB;NT6yO\|I{PSEQvF2=	NGTTXpFUSU6JRWK=
NCI-H292	NH6xXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfkVlJHUUN3ME21MlMxODR2IN88US=>	NWm4O3g5W0GQR1XS
CPC-N	NWXabVdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHyzPZFKSzVyPUWuN\|k1OTlizszN	M4XJU3NCVkeHUh?=
DoTc2-4510	M1vFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXLXGVKSzVyPUWuOFU{PzFizszN	NX3uSo9uW0GQR1XS
LB1047-RCC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjxdmtJUUN3ME21MlU2QTN\|IN88US=>	MnTvV2FPT0WU
MHH-ES-1	NHP2VI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPm[WFQUUN3ME21MlU6QTB5IN88US=>	M4\EO3NCVkeHUh?=
NMC-G1	NX;IWGdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M324W2lEPTB;NT63NFIzPyEQvF2=	MWnTRW5ITVJ?
SW1710	M4joXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M324eWlEPTB;NT63OFc2OSEQvF2=	M1j3fHNCVkeHUh?=
YAPC	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;FXZRKSzVyPUWuO\|YzODFizszN	NFLsbVlUSU6JRWK=
22RV1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnK1TWM2OD13LkiwNFE6KM7:TR?=	Mlm3V2FPT0WU
COLO-679	M{L5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPpN5hKSzVyPUWuPFg6PDhizszN	MmjzV2FPT0WU
TCCSUP	NHnYbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTVwOUOyOVkh\|ryP	NYD0OmVpW0GQR1XS
C2BBe1	NIDxXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFf3NphKSzVyPUWuPVM6PyEQvF2=	M2f2bXNCVkeHUh?=
TE-15	M33PWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnn2TWM2OD14LkC2OlA2KM7:TR?=	MYjTRW5ITVJ?
SCLC-21H	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37ZcGlEPTB;Nj6xNFg1OyEQvF2=	NGfqRZlUSU6JRWK=
EoL-1-cell	MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXuTWM2OD14LkG2OVY{KM7:TR?=	MUDTRW5ITVJ?
NKM-1	NX3CTnRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTZwMU[3NUDPxE1?	M1fkenNCVkeHUh?=
NCI-H1304	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTZwMke0Nlgh\|ryP	MmHQV2FPT0WU
NB6	M4K3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHWwPFNKSzVyPU[uNlk3OjJizszN	NGrqZ4xUSU6JRWK=
NALM-6	M2\pUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTZwM{OyN{DPxE1?	NWTHTYVrW0GQR1XS
NCI-H522	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTZwM{OzNFYh\|ryP	NEm3e2RUSU6JRWK=
MV-4-11	M2PH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfiW49KSzVyPU[uN\|cxPzlizszN	NVnCOlF4W0GQR1XS
LB2241-RCC	NVPIZVhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTZwM{i2Olch\|ryP	MmTEV2FPT0WU
NCI-H1417	NWj2RpJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\0UldKSzVyPU[uOFA5PDdizszN	NVXFUWNUW0GQR1XS
HT-1197	MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrjWFRkUUN3ME22MlU4OTJ{IN88US=>	MVnTRW5ITVJ?
P30-OHK	M{Lycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXTZ2VVUUN3ME22MlYzPzdizszN	NVTuOI1DW0GQR1XS
ALL-PO	M4HTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXL1VJlQUUN3ME22MlcyQTF4IN88US=>	MV\TRW5ITVJ?
OVCAR-4	M2PUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGD5V3NKSzVyPU[uO\|U1ODVizszN	NIDiOolUSU6JRWK=
HCC2157	M33aNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXpTWM2OD14Lke3OFc2KM7:TR?=	MVvTRW5ITVJ?
NCI-H838	NVjY[5c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLKTWM2OD14Lkm2OFkh\|ryP	MW\TRW5ITVJ?
NCI-H1299	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkK5TWM2OD14Lkm3NFkh\|ryP	MoHoV2FPT0WU
SW954	NG\LbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\jcYlSUUN3ME23MlIxODZ6IN88US=>	NH7aPWVUSU6JRWK=
NCI-H441	M3v1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTdwM{SwOlUh\|ryP	M3q1WXNCVkeHUh?=
SK-MEL-2	NF\oO\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnvOllRUUN3ME23MlQ5Ozd\|IN88US=>	MVzTRW5ITVJ?
KARPAS-45	NV[3cYxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrBTWM2OD15Lk[1PVI6KM7:TR?=	MmrqV2FPT0WU
CAL-54	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\wTWM2OD15LkiyPVc4KM7:TR?=	MVHTRW5ITVJ?
KYSE-180	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVmzeJdHUUN3ME23Mlg5QTRzIN88US=>	M2\GcHNCVkeHUh?=
NCI-H187	NUfSU216T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTdwOUW5OFch\|ryP	NWq2e\|g2W0GQR1XS
RT-112	NFntUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4faV2lEPTB;OD6wPVY4PyEQvF2=	MUDTRW5ITVJ?
NCI-H1437	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnJU\|dmUUN3ME24MlA6Pzl3IN88US=>	MV3TRW5ITVJ?
SNU-449	NIe2NZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LRc2lEPTB;OD6yPFI4OiEQvF2=	NHzYbmhUSU6JRWK=
HCC1187	M{\jPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPGTWM2OD16LkK5N\|kyKM7:TR?=	MVPTRW5ITVJ?
NCI-H2030	M4XnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnDXJNRUUN3ME24MlM4PzF2IN88US=>	MUnTRW5ITVJ?
HuO-3N1	MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRThwM{e4OFQh\|ryP	NUTwNVlMW0GQR1XS
COLO-792	NXPrTJNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrwOZpKSzVyPUiuOFE2OjdizszN	MmfiV2FPT0WU
MIA-PaCa-2	MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXqze2RvUUN3ME24Mlg2PTB6IN88US=>	MmfxV2FPT0WU
SK-N-FI	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3T5OWlEPTB;OT6wOFI2KM7:TR?=	NFrtNXJUSU6JRWK=
MMAC-SF	NULjfnpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVznZZJLUUN3ME25MlA6PzVzIN88US=>	MV3TRW5ITVJ?
NCI-H28	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTlwMUC0Olkh\|ryP	MljCV2FPT0WU
ETK-1	NYXkdYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTlwMkm5O\|Qh\|ryP	NF7ybHJUSU6JRWK=
NCI-H1993	NYjvZ4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTlwNESyOlEh\|ryP	NGDGW3dUSU6JRWK=
no-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37nR2lEPTB;OT60O\|EzKM7:TR?=	MlS5V2FPT0WU
ChaGo-K-1	NGLzeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTlVGlKSzVyPUmuOVE2QDNizszN	MmXOV2FPT0WU
NCCIT	NIjzfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\3TlJGUUN3ME25MlU{OTZ7IN88US=>	NYPofGJZW0GQR1XS
SAS	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPs[oJKSzVyPUGwMlI1QCEQvF2=	Mnz0V2FPT0WU
A673	NHXNU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jCT2lEPTB;MUCuN\|cxPCEQvF2=	M1PW[3NCVkeHUh?=
NCI-H1522	M{LudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7ETWM2OD1zMD6zO\|A4KM7:TR?=	NHrmWnhUSU6JRWK=
NCI-H810	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTFyLkO5NFch\|ryP	M321cXNCVkeHUh?=
IST-MES1	NVvKOWd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnKd5VPUUN3ME2xNE41PTZ2IN88US=>	MX\TRW5ITVJ?
GR-ST	NXm4WG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoD6TWM2OD1zMD61NFI1KM7:TR?=	MYXTRW5ITVJ?
SUP-T1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPWZoxKSzVyPUGwMlc{OTdizszN	MWnTRW5ITVJ?
NB5	NF3JUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljPTWM2OD1zMD65NFIzKM7:TR?=	MkTZV2FPT0WU
MZ1-PC	M4fFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M330VGlEPTB;MUCuPVU4OSEQvF2=	NFnlNm1USU6JRWK=
SK-CO-1	M3fZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\w[GJKSzVyPUGwMlk6OzFizszN	MV\TRW5ITVJ?
Capan-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\sTVNKSzVyPUGxMlMyQThizszN	Mn;HV2FPT0WU
697	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\XS3NxUUN3ME2xNU43PzV5IN88US=>	NXn3endsW0GQR1XS
REH	M4T3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XMeWlEPTB;MUGuO\|Q2OSEQvF2=	NF7aTGdUSU6JRWK=
GI-1	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfwVVRKSzVyPUGxMlg3OTVizszN	NYHhW3BrW0GQR1XS
BB65-RCC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrxTWM2OD1zMj6wPVE3KM7:TR?=	M3rGcXNCVkeHUh?=
NCI-H1651	NF72fmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTF{LkK0O\|gh\|ryP	MnLaV2FPT0WU
NCI-H1618	NGPkTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NICyVmlKSzVyPUGyMlM6PzZizszN	MYjTRW5ITVJ?
NCI-H2081	NF\PVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jLeWlEPTB;MUKuOlE1OSEQvF2=	M{G4XXNCVkeHUh?=
GCIY	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTF{LkeyNVMh\|ryP	MmmwV2FPT0WU
NY	MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY[zZZBpUUN3ME2xN{4xPjR\|IN88US=>	NHvv[5lUSU6JRWK=
PANC-03-27	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlP4TWM2OD1zMz6wPFA4KM7:TR?=	MXjTRW5ITVJ?
BHY	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYniS2NMUUN3ME2xN{4zOTJzIN88US=>	MkHlV2FPT0WU
SK-OV-3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTF\|LkO3OlMh\|ryP	M4H0TXNCVkeHUh?=
5637	NUT0V4IyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUK1bnJRUUN3ME2xN{44PzV7IN88US=>	MYDTRW5ITVJ?
LC-1F	NHnpfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTLTWM2OD1zND6wN\|U3KM7:TR?=	NVf4SnE3W0GQR1XS
SNB75	MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTF2LkCzPFMh\|ryP	MUnTRW5ITVJ?
CHP-212	NVfsSGhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfjb2tXUUN3ME2xOE4xPDZ2IN88US=>	M3PMTXNCVkeHUh?=
HT-1376	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXrcHk2UUN3ME2xOE4yOTJ4IN88US=>	NGK0UZhUSU6JRWK=
MONO-MAC-6	NXq0NJVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTF2LkG1NFIh\|ryP	MmD5V2FPT0WU
CA46	NFvVU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFn6[Y5KSzVyPUG0MlE5OjdizszN	M4LwRXNCVkeHUh?=
SCC-15	Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\SRopnUUN3ME2xOE42PTh\|IN88US=>	NH\pXpBUSU6JRWK=
ATN-1	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTF2Lk[2Nlch\|ryP	MnezV2FPT0WU
NCI-H2405	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnziTWM2OD1zND64NVU4KM7:TR?=	NX\CNVUyW0GQR1XS
NCI-H716	NVH1SFUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rtSGlEPTB;MUSuPFQ6OyEQvF2=	Mk\RV2FPT0WU
SW620	NWfheWtST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTF2LkmwNVQh\|ryP	NFHzWWFUSU6JRWK=
NCI-H226	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37CSWlEPTB;MUSuPVA5PSEQvF2=	MmXNV2FPT0WU
SW962	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7tTWM2OD1zND65OFMzKM7:TR?=	MX7TRW5ITVJ?
KYSE-150	MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljoTWM2OD1zND65OVUh\|ryP	MlT4V2FPT0WU
OCUB-M	NHHF[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTvTWM2OD1zND65PFg{KM7:TR?=	NH;t[IJUSU6JRWK=
ES7	Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\iTVBEUUN3ME2xOU4xQTh2IN88US=>	NVXxN2x7W0GQR1XS
SW1463	NVv0TG1ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfMTWM2OD1zNT60NlI{KM7:TR?=	NYPuRZlvW0GQR1XS
CAKI-1	M2DEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLUc\|FYUUN3ME2xOU42OzR4IN88US=>	NH;GOI9USU6JRWK=
MKN28	NFnxcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jMdGlEPTB;MUWuOVQ4QSEQvF2=	MWDTRW5ITVJ?
SW13	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonhTWM2OD1zNT62NVgh\|ryP	MWDTRW5ITVJ?
A3-KAW	M2XNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojoTWM2OD1zNT65Olk4KM7:TR?=	MUXTRW5ITVJ?
LU-65	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4ewWWlEPTB;MUWuPVc3QCEQvF2=	M1\BTXNCVkeHUh?=
Calu-1	M4e2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfa[YlKSzVyPUG2MlA{PjhizszN	MWTTRW5ITVJ?
ST486	NHjpN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPsNIVKSzVyPUG2MlA1OzFizszN	MWfTRW5ITVJ?
BB30-HNC	M{D0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF32TnpKSzVyPUG2MlEzPDZizszN	MX7TRW5ITVJ?
EGI-1	M2DHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfISXRKSzVyPUG2MlQ1PiEQvF2=	M2ftPXNCVkeHUh?=
SH-4	MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjCfVNFUUN3ME2xOk41PzNzIN88US=>	MnG2V2FPT0WU
MN-60	MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPFTWM2OD1zNz6yNlk4KM7:TR?=	MVjTRW5ITVJ?
MPP-89	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXNTWM2OD1zNz6yOFU6KM7:TR?=	M4HTXHNCVkeHUh?=
A2780	NH;MRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoS3TWM2OD1zNz60NVM6KM7:TR?=	NGHWcFVUSU6JRWK=
Daoy	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTqd29zUUN3ME2xO{41Pjl3IN88US=>	NIXLdm9USU6JRWK=
NCI-H2126	NVXHZVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1L4TGlEPTB;MUeuOFc4OSEQvF2=	NE\T[YZUSU6JRWK=
NCI-H1563	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFS2TW5KSzVyPUG3MlQ6OTdizszN	M1zRb3NCVkeHUh?=
8-MG-BA	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjqXGhKSzVyPUG3MlY3PDhizszN	NVrPb\|l7W0GQR1XS
786-0	NHfk[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTF5LkizOVMh\|ryP	M4PndnNCVkeHUh?=
AM-38	MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXwNm5KSzVyPUG3Mlk{ODZizszN	NV:0W2VCW0GQR1XS
COLO-824	MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPN[mVHUUN3ME2xPE41PDN4IN88US=>	MmrhV2FPT0WU
SK-MEL-30	NXPYbItYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTF6LkWwPFIh\|ryP	MVHTRW5ITVJ?
CESS	NH7EN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPEUI9KSzVyPUG4Mlc3ODlizszN	MXHTRW5ITVJ?
BL-70	NWHReGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHVWo5KSzVyPUG4MlgyPTZizszN	Ml\QV2FPT0WU
NCI-H2170	M3L2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPVTWM2OD1zOD65NVc6KM7:TR?=	MmTEV2FPT0WU
HT-3	M{HlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXQTW9oUUN3ME2xPE46QDNizszN	MmLmV2FPT0WU
BOKU	NGnsO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDqdpNxUUN3ME2xPU4xOzhzIN88US=>	M1PrSnNCVkeHUh?=
HPAF-II	NXXZN3Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHJPXFZUUN3ME2xPU4{ODF3IN88US=>	NF;6RWFUSU6JRWK=
KGN	NVu4XIdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\V[2FKSzVyPUG5MlQ4PjVizszN	NVPZeZpWW0GQR1XS
MC-CAR	NWX6[ZpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPaVng5UUN3ME2xPU43OzF\|IN88US=>	MnTJV2FPT0WU
BHT-101	NV\tcmpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkmwTWM2OD1zOT63O\|ch\|ryP	Mn3PV2FPT0WU
SW1783	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV[zZ2JCUUN3ME2xPU44QDB4IN88US=>	NUHDTVlXW0GQR1XS
KP-N-YN	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXL5NWtjUUN3ME2yNE4xOjZ{IN88US=>	Mn7ZV2FPT0WU
LU-165	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{OwTmlEPTB;MkCuOVU4OSEQvF2=	NV\JNHJXW0GQR1XS
GOTO	NGi0U2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TC[mlEPTB;MkCuOlQ2OSEQvF2=	M4fzeHNCVkeHUh?=
EFM-19	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PDXmlEPTB;MkGuNFcyPiEQvF2=	NInLfpRUSU6JRWK=
CTV-1	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHDfHlKSzVyPUKxMlExPTRizszN	MV3TRW5ITVJ?
HEL	NU\Gb5RHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTJzLkSyNVYh\|ryP	NGmySYxUSU6JRWK=
SNU-C2B	MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fRdmlEPTB;MkGuOFI3KM7:TR?=	MWfTRW5ITVJ?
ECC4	NGi5OVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTJzLkewO{DPxE1?	MXTTRW5ITVJ?
NEC8	M2jrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHL0dGZKSzVyPUKxMlg{PjhizszN	MXrTRW5ITVJ?
KMOE-2	M2\vXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2P2eGlEPTB;MkGuPFkzOSEQvF2=	MX\TRW5ITVJ?
NCI-H524	MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTr[3pKSzVyPUKyMlA5ODhizszN	MVTTRW5ITVJ?
WSU-NHL	M1Pvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV[ycYFQUUN3ME2yNk4yPTd5IN88US=>	M2iwTHNCVkeHUh?=
SF126	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2i1cWlEPTB;MkKuNlQ3QSEQvF2=	NVnLVFROW0GQR1XS
HOP-92	NIjVfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfXPGVCUUN3ME2yNk4{OTZ5IN88US=>	MYjTRW5ITVJ?
CTB-1	NEjaXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTJ{LkS2O\|ch\|ryP	M1XYR3NCVkeHUh?=
KYSE-270	NYXZb4pJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPGWYFKSzVyPUKyMlk{PTdizszN	NEfqbGVUSU6JRWK=
SK-MEL-24	MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTJ\|LkG4O{DPxE1?	MUHTRW5ITVJ?
Calu-3	NETWcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTJ\|LkKxNlgh\|ryP	NUfNVGJpW0GQR1XS
GAMG	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXWzUnJoUUN3ME2yN{4zOzZ5IN88US=>	NWLKTItoW0GQR1XS
SW1573	Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTJ\|Lke0NVUh\|ryP	Ml;MV2FPT0WU
MHH-NB-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zDeWlEPTB;MkSuNFE6PCEQvF2=	MWXTRW5ITVJ?
TK10	NUP2UXZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTxW4F2UUN3ME2yOE42ODF\|IN88US=>	NX2zfWFKW0GQR1XS
LB373-MEL-D	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvLWow4UUN3ME2yOE43ODZ2IN88US=>	Mn3IV2FPT0WU
KALS-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTJ2LkezNlch\|ryP	MXLTRW5ITVJ?
HUTU-80	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIf3[G5KSzVyPUK1MlgxOzJizszN	MYDTRW5ITVJ?
HuP-T3	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVWzdXpRUUN3ME2yOk4yPjd2IN88US=>	MlqzV2FPT0WU
OE19	NUjCfoFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYThRno2UUN3ME2yOk4zOTV\|IN88US=>	MkLLV2FPT0WU
J82	NFHTXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn2yTWM2OD1{Nj6yOFcyKM7:TR?=	NEDLNppUSU6JRWK=
DU-4475	NYS0SIxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnoRXRKSzVyPUK2MlM5OTlizszN	MV7TRW5ITVJ?
DMS-53	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPkd413UUN3ME2yOk42OTN6IN88US=>	MUnTRW5ITVJ?
COLO-741	NVju[VQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoOzTWM2OD1{Nj64N\|Q1KM7:TR?=	NYHJ[oZuW0GQR1XS
SW48	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfrOGlKSzVyPUK2Mlg5OiEQvF2=	NFrEbJBUSU6JRWK=
IGR-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEH2cFlKSzVyPUK2Mlk{OzRizszN	MlvyV2FPT0WU
639-V	M4XvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2GxWWlEPTB;MkeuNFI1PSEQvF2=	MkToV2FPT0WU
LK-2	MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofhTWM2OD1{Nz60NVQyKM7:TR?=	NWPQU2JuW0GQR1XS
NCI-H2347	MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXmfFlKSzVyPUK3Mlk3QTlizszN	M3qwdXNCVkeHUh?=
NCI-H2228	NVXZ[op4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XLfGlEPTB;MkiuNFkxPSEQvF2=	MlzGV2FPT0WU
LS-123	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nZSmlEPTB;MkiuNVI3OiEQvF2=	NXPBRpMxW0GQR1XS
U031	MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTJ6LkK1NkDPxE1?	MnL3V2FPT0WU
NCI-H1792	M1\Ffmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYK1[mR2UUN3ME2yPE41PzJzIN88US=>	NFXZWHJUSU6JRWK=
NCI-H2087	NUPuO\|FmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1u0S2lEPTB;MkiuO\|U2OiEQvF2=	MmnmV2FPT0WU
NCI-H2342	NULaNmZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfnN3c2UUN3ME2yPU42OjB6IN88US=>	NWrUdItNW0GQR1XS
SW626	NXLjfFV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PHUWlEPTB;MkmuO\|U3KM7:TR?=	NHu3R4JUSU6JRWK=
LB2518-MEL	M1jjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXmfoY4UUN3ME2yPU45OTVizszN	MXLTRW5ITVJ?
RXF393	NUTFNYZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fEOGlEPTB;M{CuNFk2OiEQvF2=	MUDTRW5ITVJ?
LC4-1	MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTITWM2OD1\|MD6zNFkzKM7:TR?=	M2S2b3NCVkeHUh?=
NCI-H1694	NEK2eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXNTYF4UUN3ME2zNE43PjJ2IN88US=>	MkXRV2FPT0WU
K5	NFK0RoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDaT2dXUUN3ME2zNE46PzB{IN88US=>	NHexbmtUSU6JRWK=
HDLM-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{W2OGlEPTB;M{CuPVczPSEQvF2=	M1XwXHNCVkeHUh?=
BCPAP	MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{W1OWlEPTB;M{GuPFM4QSEQvF2=	NH7XRWxUSU6JRWK=
BC-3	NH7FU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTN{LkG0NFMh\|ryP	NUnzNmFjW0GQR1XS
LB996-RCC	NXPsTIh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzz[Y9KSzVyPUOyMlI{PThizszN	NWjOWXhRW0GQR1XS
NCI-H2009	M4fWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVq5O3M2UUN3ME2zNk41QThzIN88US=>	NVTYd3FFW0GQR1XS
HTC-C3	NXW3UmdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzWTWM2OD1\|Mz63OVE6KM7:TR?=	NGPCUo5USU6JRWK=
LAMA-84	MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPEPIRKSzVyPUO0MlQ1ODdizszN	M2DDTXNCVkeHUh?=
CCRF-CEM	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHjV3AxUUN3ME2zOE42PzF3IN88US=>	NH\VdHZUSU6JRWK=
AN3-CA	NGe5O5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHK[IRoUUN3ME2zOU4xPTZ6IN88US=>	Mm\RV2FPT0WU
NCI-H1734	NFHRblVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTN3LkK1OlEh\|ryP	NIf6VYNUSU6JRWK=
Ca-Ski	NGPMTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPwVXBkUUN3ME2zOU41OTBzIN88US=>	Mo\OV2FPT0WU
U-266	Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3nUFR5UUN3ME2zOU43OTF2IN88US=>	NF7ueXhUSU6JRWK=
SBC-5	MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TpNWlEPTB;M{WuO\|c5OSEQvF2=	NX\sRWxpW0GQR1XS
GT3TKB	MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTN5LkGxOUDPxE1?	MlPQV2FPT0WU
MDA-MB-175-VII	Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInXVGJKSzVyPUO3MlIzPDhizszN	MX7TRW5ITVJ?
PFSK-1	NUfsco11T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYD5UZM3UUN3ME2zO{4zPDN3IN88US=>	M{fQ[3NCVkeHUh?=
IMR-5	MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTN5LkK0PFch\|ryP	M4L3T3NCVkeHUh?=
Daudi	MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXEfmNzUUN3ME2zO{4{PTl5IN88US=>	MmW4V2FPT0WU
A498	NV7WS\|M{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTN5LkeyNVgh\|ryP	MkjqV2FPT0WU
SCC-4	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPMblUyUUN3ME2zO{44QDR\|IN88US=>	NWnKXGFFW0GQR1XS
COLO-680N	M{LGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTN6LkK4PFUh\|ryP	MoLwV2FPT0WU
SK-MES-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjiTWM2OD1\|OD6zNlE2KM7:TR?=	MkDpV2FPT0WU
SR	NVLERolvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\pTWM2OD1\|OD61OFk2KM7:TR?=	MX;TRW5ITVJ?
LNCaP-Clone-FGC	NWXETZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLRTWM2OD1\|OD61OlM4KM7:TR?=	NWfKPWtbW0GQR1XS
SK-HEP-1	M2nST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYD6coRnUUN3ME2zPE44QDJ{IN88US=>	M2[4WnNCVkeHUh?=
BPH-1	NVT6VoNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPYU3pTUUN3ME2zPE45OzJ7IN88US=>	NIPzfGxUSU6JRWK=
NCI-H1755	NFf2[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HlR2lEPTB;M{muOVgyPyEQvF2=	MnPvV2FPT0WU
LXF-289	NVnSS49KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTN7LkiwPFQh\|ryP	Mn3GV2FPT0WU
SW1088	M4TG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\yTWM2OD12MD6yNVA4KM7:TR?=	NFPhZnRUSU6JRWK=
MOLT-4	NX\nVoNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LiXWlEPTB;NECuNlkxOSEQvF2=	M1:xbnNCVkeHUh?=
AsPC-1	M2Xse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;WU4dKSzVyPUSwMlQ2QDNizszN	MnrQV2FPT0WU
HOP-62	M{TuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTRyLk[1Olgh\|ryP	M12xTHNCVkeHUh?=
A172	M3PaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\pTWM2OD12MD64OVEyKM7:TR?=	MnnyV2FPT0WU
SN12C	NVKwNFh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;oTWM2OD12MD65N\|g2KM7:TR?=	M1;VPHNCVkeHUh?=
MDA-MB-231	NI\XdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PEdmlEPTB;NECuPVg6QCEQvF2=	NEX5R41USU6JRWK=
RPMI-2650	NXXuU3N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGmyZVlKSzVyPUSxMlE2QTNizszN	M1jWeHNCVkeHUh?=
KYSE-140	NUi2e\|RlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTRzLkixNlMh\|ryP	MU\TRW5ITVJ?
KINGS-1	NXHBNG1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vqOGlEPTB;NEKuOFY6PyEQvF2=	M3zhW3NCVkeHUh?=
HSC-3	M2fOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPyTWM2OD12Mj62OlYyKM7:TR?=	MoLKV2FPT0WU
PC-14	M3;oU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlT3TWM2OD12Mz6xPFgzKM7:TR?=	Mn[3V2FPT0WU
COR-L105	MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTR\|Lk[1NFIh\|ryP	MUHTRW5ITVJ?
BE-13	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfWPYhNUUN3ME20OE4zOzdzIN88US=>	NYnvSZNYW0GQR1XS
NCI-H661	NIjMU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDUNWZFUUN3ME20OE4zQTV6IN88US=>	M2LTdXNCVkeHUh?=
IST-MEL1	NVjTbmJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETLUmJKSzVyPUS0MlM2QTlizszN	M3ftOnNCVkeHUh?=
HCC1806	M1HxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\lemJKSzVyPUS0MlU5PzNizszN	MXfTRW5ITVJ?
COLO-800	M3HsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIj6SlFKSzVyPUS0Mlg1PTNizszN	NF72e4pUSU6JRWK=
IST-SL2	MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjWSmdKSzVyPUS1MlEzPDdizszN	M1TMNnNCVkeHUh?=
8305C	MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XKWGlEPTB;NEWuN\|A6KM7:TR?=	NHL1SGZUSU6JRWK=
UACC-62	M{jrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHntUHRKSzVyPUS2MlI5PzVizszN	MmrCV2FPT0WU
COR-L23	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPWTWM2OD12Nz6xPVkh\|ryP	MYfTRW5ITVJ?
EFE-184	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDCVnRmUUN3ME20O{4{QDhizszN	NYrHNpVEW0GQR1XS
DMS-114	NULlZmlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXZe3dKSzVyPUS3MlQyPDlizszN	MX3TRW5ITVJ?
KYSE-520	M2\JU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTR6LkWzNVUh\|ryP	Mm\EV2FPT0WU
SNG-M	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTR7LkSzOEDPxE1?	NHXv[VdUSU6JRWK=
A2058	MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmi2TWM2OD12OT60PFg2KM7:TR?=	NHewbotUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	- Collapse Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(O)CC(C1)C2=NC(=C3[N]2C=CN=C3N)C4=CC=C5C=CC(=NC5=C4)C6=CC=CC=C6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). Picropodophyllin (PPP) induces apoptosis with antineoplastic activity.
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib（R428) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)